A Phase IV Clinical Trial of Patients with Solid Tumors Receiving Lenograstim as Primary Prophylaxis for Chemotherapy-Induced Neutropenia, in a Docetaxel-Based Regimen
Table 4
Reasons for docetaxel-based chemotherapy dose delays and changes.
Reason
Number (%) of patients with ≥1 treatment delay
Number (%) of patients with ≥1 dose change
Amount of patients with at least one dose delay/change
85 (21.6)
144 (36.5)
Febrile neutropenia
2 (0.5)
4 (1.0)
Neutropenia
32 (8.1)
32 (8.1)
Anemia
1 (0.25)
9 (2.3)
Myalgia
1 (0.25)
8 (2.0)
Asthenia
2 (0.5)
6 (1.5)
Oral mucositis
—
4 (1.0)
Nail ridging
—
1 (0.25)
Infection (other than febrile neutropenia)
11 (2.8)
4 (1.0)
Other adverse events
8 (2.0)
22 (5.6)
Patient’s personal convenience
17 (4.3)
—
Medical funder/insurance related
11 (2.8)
4 (1.0)
Other
12 (3.0)
90 (22.8)
The percentage is calculated out of the 394, the total number of patients in the study’s cohort. A patient may have more than one reason recorded for change or delay in treatment.
